Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG assumes coverage of Bionano Genomics at buy; PT $3.50

BTIG analyst Mark Massaro assumed coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and price target of $3.50. The stock closed at $2.16 on Dec. 9. Bionano provides optical genome mapping technology tools...

December 12, 2022

Markets

HCW starts Enanta Pharma at buy; PT $56

H.C. Wainwright initiated coverage of Enanta Pharmaceuticals (NASDAQ:ENTA) with a “buy” rating and $56 price target. The stock closed at $41.78 on Dec. 8. Enanta’s claim to fame is the discovery of glecaprevir...

December 9, 2022

Markets

Maxim ups NLS Pharma to buy on funding from BVF Partners

Maxim Group upgraded NLS Pharmaceuticals (NASDAQ:NLSP) to “buy” from “hold” with a new $4 price target. The stock closed at 88 cents on Dec. 7 when NLS announced a purchase agreement with BVF Partners, a leading...

December 8, 2022

Markets

HCW starts Opthea at buy; PT $14

H.C. Wainwright launched coverage of Opthea (NASDAQ:OPT) with a “buy” rating and $14 price target. The stock closed at $4.97 on Dec. 7. Opthea is focused on patients suffering from retinal eye diseases, such as wet age...

December 8, 2022

Markets

Maxim starts Blue Water Vaccines at buy; PT $4

Maxim Group initiated coverage of Blue Water Vaccines (NASDAQ:BWV) with a “buy” rating and price target of $4. The stock closed at $1.15 on Dec. 7. Blue Water is developing a portfolio of vaccine candidates targeting...

December 8, 2022

Markets

BTIG ups Aerovate to buy on competitor data

BTIG upgraded Aerovate Therapeutics (NASDAQ:AVTE) to “buy” from “neutral” with a $27 price target, citing Gossamer Bio’s TORREY results that could validate Aerovate’s dry powder inhalation (DPI) administered tyrosine...

December 6, 2022

Markets

HCW starts ImmunoPrecise Antibodies at buy; PT $9

H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies (NASDAQ:IPA) with a “buy” rating and price target of $9. The stock closed at $4.93 on Dec. 1. ImmunoPrecise is a contract research organization (CRO) that...

December 2, 2022

Markets

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) released updated interim data from its Phase 2 pivotal trial with its key value driver, TLD-1433, activated by its proprietary TLC-3200 medical laser system, that Research...

November 30, 2022

Markets

Stifel starts OmniAb at buy; PT $12

Stifel launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and $12 price target. The stock closed at $2.61 on Nov. 25. Analyst Stephen Willey writes that OmniAb represents the construction of a high-throughput...

November 28, 2022

Markets

HCW ups BerGenBio to buy on positive outlook for bemcentinib

H.C. Wainwright upgraded BerGenBio (OSLO:BGBIO) to “buy” from “neutral” with a price target of NOK30. The stock closed at NOK6.70 on Nov. 25. “As 2022 is coming to a close, we believe now is an opportune time to step...

November 28, 2022

Markets

Maxim starts Cingulate at buy; PT $3

Maxim Group launched coverage of Cingulate (NASDAQ:CING) with a “buy” rating and price target of $3. The stock closed at 69 cents on Nov. 21. Cingulate is a Phase 3-ready company developing multiple therapies for...

November 22, 2022

Markets

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

November 22, 2022

Markets

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

November 21, 2022

Markets

Cantor ups Provention Bio PT on FDA T1D approval

Cantor Fitzgerald raised its price target for Provention Bio (NASDAQ:PRVB) to $16 from $12 and maintained an “overweight” rating after the FDA approved teplizumab (brand name, TZIELD) to delay the onset of Type 1...

November 18, 2022

Markets

Cantor starts KemPharm at OW; PT $20

Cantor Fitzgerald initiated coverage of KemPharm (NASDAQ:KMPH) with an “overweight’ rating and a 12-month discounted cash flow-based price target of $20. The stock closed at $4.39 on Nov. 16. “We think KemPharm’s...

November 17, 2022

Markets

Cantor starts Theratechnologies at OW; PT $9

Cantor Fitzgerald launched coverage of Theratechnologies (NASDAQ:THTX) with an “overweight” rating and $9 price target. The stock closed at $1.88 on Nov. 16. “We believe the peak sales potential of Theratechnologies’...

November 17, 2022

Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022

Markets

SVB cuts Satsuma to MP after negative SUMMIT data

SVB Securities downgraded Satsuma Pharmaceuticals (NASDAQ:STSA) to “market perform” from “outperform” and slashed its price target to $1 from $15 after the company reported negative data for the Phase 3 SUMMIT trial of...

November 15, 2022

Markets

WB starts Janux Therapeutics at OP

William Blair initiated coverage of Janux Therapeutics (NASDAQ:JANX) with an “outperform” rating based on the potential of the company’s TRACTr platform, which facilitates the generation of conditionally active T-cell...

November 14, 2022

Markets

BTIG cuts OncoSec to neutral on updated Phase 2 results

BTIG downgraded OncoSec Medical (NASDAQ:ONCS) to “neutral” from “buy” and removed its price target after the company reported updated Phase 2 Keynote-695 study results. The stock closed at $4.66 on Nov. 11. Analyst...

November 14, 2022

Markets

Leede Jones Gable cuts Medical Facilities to hold on EBITDA margins

Leede Jones Gable downgraded Medical Facilities (TSX:DR) to “hold” from “buy” and lowered its price target to $9.25 (Canadian) from $12, citing solid top-line data in the third quarter of 2022, offset by cost pressures...

November 11, 2022

Markets

Maxim ups Reviva PT to $10 on rising Phase 3 enrollment

Maxim Group raised its price target for Reviva Pharmaceuticals (NASDAQ:RVPH) to $10 from $3 after the company’s ongoing Phase 3 study in schizophrenia reached more than 30% enrollment, of total 400 patients, at sites in...

November 1, 2022

BTIG assumes coverage of Bionano Genomics at buy; PT $3.50

HCW starts Enanta Pharma at buy; PT $56

Maxim ups NLS Pharma to buy on funding from BVF Partners

HCW starts Opthea at buy; PT $14

Maxim starts Blue Water Vaccines at buy; PT $4

BTIG ups Aerovate to buy on competitor data

HCW starts ImmunoPrecise Antibodies at buy; PT $9

Research Capital: Theralase bladder cancer data trending ahead of Keytruda

Stifel starts OmniAb at buy; PT $12

HCW ups BerGenBio to buy on positive outlook for bemcentinib

Maxim starts Cingulate at buy; PT $3

SVB starts Trevi Therapeutics at OP; PT $6

BTIG starts Cullinan Oncology at buy; PT $20

Cantor ups Provention Bio PT on FDA T1D approval

Cantor starts KemPharm at OW; PT $20

Cantor starts Theratechnologies at OW; PT $9

HCW ups Syros PT on optimism about AML data at ASH

SVB cuts Satsuma to MP after negative SUMMIT data

WB starts Janux Therapeutics at OP

BTIG cuts OncoSec to neutral on updated Phase 2 results

Leede Jones Gable cuts Medical Facilities to hold on EBITDA margins

Maxim ups Reviva PT to $10 on rising Phase 3 enrollment

General

More